Limits...
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus

Clinical scores and body weight curves of rats in each group. (A) Clinical score curves of rats in each group 0–18 days post-immunization. Compared with the naive group, the clinical score in the vehicle group was significantly increased (P<0.01). Compared with the vehicle group, clinical scores in the TSIIA-treated groups were reduced significantly (both P<0.01), and there was a significant difference between the two treated groups (P<0.01). (B) Body weight curves of rats in each group. Significant weight loss was observed in the vehicle group compared with the naïve group (P<0.01), while the two TSIIA-treated groups exhibited significantly increased body weights compared with the vehicle group (P<0.01), and there was a significant difference between the TSIIA-L and TSIIA-H groups (P<0.01). Values are presented as the mean ± standard deviation (n=10 per group). TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940100&req=5

f1-mmr-14-02-1601: Clinical scores and body weight curves of rats in each group. (A) Clinical score curves of rats in each group 0–18 days post-immunization. Compared with the naive group, the clinical score in the vehicle group was significantly increased (P<0.01). Compared with the vehicle group, clinical scores in the TSIIA-treated groups were reduced significantly (both P<0.01), and there was a significant difference between the two treated groups (P<0.01). (B) Body weight curves of rats in each group. Significant weight loss was observed in the vehicle group compared with the naïve group (P<0.01), while the two TSIIA-treated groups exhibited significantly increased body weights compared with the vehicle group (P<0.01), and there was a significant difference between the TSIIA-L and TSIIA-H groups (P<0.01). Values are presented as the mean ± standard deviation (n=10 per group). TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.

Mentions: Clinical signs of EAE development in rats from the vehicle group began to appear on day 9 p.i., including loss of appetite, reduced physical activity, and tail and limb paralysis. However, EAE onset in TSIIA-treated rats occurred on day 11 p.i. (TSIIA-H) and 10 p.i. (TSIIA-L). Compared with the vehicle group, the two TSIIA-treated groups received significantly lower clinical scores (P<0.01). Significant differences were also observed between the treated groups, which were dose-dependent (P<0.01; Fig. 1A). Furthermore, the body weights of untreated EAE rats were significantly decreased, compared with the naive and TSIIA-treated rats (all P<0.01) while those of TSIIA-treated groups were only marginally reduced, with the smallest recorded weight loss in the TSIIA-H group. Significant differences in body weight were observed between the two treatment groups (P<0.01; Fig. 1B).


Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Clinical scores and body weight curves of rats in each group. (A) Clinical score curves of rats in each group 0–18 days post-immunization. Compared with the naive group, the clinical score in the vehicle group was significantly increased (P<0.01). Compared with the vehicle group, clinical scores in the TSIIA-treated groups were reduced significantly (both P<0.01), and there was a significant difference between the two treated groups (P<0.01). (B) Body weight curves of rats in each group. Significant weight loss was observed in the vehicle group compared with the naïve group (P<0.01), while the two TSIIA-treated groups exhibited significantly increased body weights compared with the vehicle group (P<0.01), and there was a significant difference between the TSIIA-L and TSIIA-H groups (P<0.01). Values are presented as the mean ± standard deviation (n=10 per group). TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940100&req=5

f1-mmr-14-02-1601: Clinical scores and body weight curves of rats in each group. (A) Clinical score curves of rats in each group 0–18 days post-immunization. Compared with the naive group, the clinical score in the vehicle group was significantly increased (P<0.01). Compared with the vehicle group, clinical scores in the TSIIA-treated groups were reduced significantly (both P<0.01), and there was a significant difference between the two treated groups (P<0.01). (B) Body weight curves of rats in each group. Significant weight loss was observed in the vehicle group compared with the naïve group (P<0.01), while the two TSIIA-treated groups exhibited significantly increased body weights compared with the vehicle group (P<0.01), and there was a significant difference between the TSIIA-L and TSIIA-H groups (P<0.01). Values are presented as the mean ± standard deviation (n=10 per group). TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
Mentions: Clinical signs of EAE development in rats from the vehicle group began to appear on day 9 p.i., including loss of appetite, reduced physical activity, and tail and limb paralysis. However, EAE onset in TSIIA-treated rats occurred on day 11 p.i. (TSIIA-H) and 10 p.i. (TSIIA-L). Compared with the vehicle group, the two TSIIA-treated groups received significantly lower clinical scores (P<0.01). Significant differences were also observed between the treated groups, which were dose-dependent (P<0.01; Fig. 1A). Furthermore, the body weights of untreated EAE rats were significantly decreased, compared with the naive and TSIIA-treated rats (all P<0.01) while those of TSIIA-treated groups were only marginally reduced, with the smallest recorded weight loss in the TSIIA-H group. Significant differences in body weight were observed between the two treatment groups (P<0.01; Fig. 1B).

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus